+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

North America Genotyping Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product and Services, Technology, Application, and End User

  • PDF Icon

    Report

  • 157 Pages
  • September 2022
  • Region: North America
  • The Insight Partners
  • ID: 5668439
UP TO OFF until Dec 31st 2024
The genotyping market in North America is expected to grow from US$ 11,734.10 million in 2022 to US$ 37,599.28 million by 2028. It is estimated to grow at a CAGR of 21.4% from 2022 to 2028.

Genotyping compares a DNA sequence to another sample or a reference sequence to discover variations in genetic complement. It detects single-nucleotide polymorphisms (SNPs), which are minor differences in genetic sequence within the population. The human genome has about 660 million SNPs, making them the most prevalent kind of genetic variation. They can explain features such as eye color and hereditary disorders such as cystic fibrosis and sickle cell anemia and serve as indicators for developing complicated diseases, such as cancer, diabetes, and Alzheimer's.

According to the Alzheimer's Association, the number of people living with Alzheimer's in the US is rapidly increasing. Alzheimer's affects more than 6 million Americans of all ages. In 2022, an estimated 6.5 million Americans aged 65 and up have Alzheimer's, out of which 73% of the population is 75 years old or older. The introduction of high-throughput genotyping technologies has greatly advanced our understanding of the genetic components of complex disorders, such as T2D.

Additionally, by comparing polymorphisms in two distinct populations (one healthy and one diseased), genome-wide association studies (GWAS) can uncover links between SNPs and common illness risk. GWAS can begin to untangle the molecular mechanisms underlying disease states by finding probable causative variables risk stratification. Single-celled organisms, such as bacteria, even have SNPs. SNP genotyping can discriminate between microorganism isolates and might even be accustomed to characterizing antibiotic resistance strains. SNP-based strain detection has relevance in each clinical and pharmaceutical analysis and has been used to study the spread of infectious diseases in humans. Since these conditions are difficult to identify clinically, genotyping is the backbone of diagnostic testing in the population. This rising adoption of prenatal genetic screening to examine children's chromosomal anomalies could prove to be a significant driving factor.

Over the last decade, next-generation sequencing (NGS) technology has enabled simultaneous testing of multiple disease genes, from targeted gene panels to exome sequencing (ES) and genomic sequencing (GS). GS is quickly becoming a practical first-stage test as costs decrease and performance improves. More and more studies show that GS can detect an unprecedented range of pathogenic abnormalities in a single laboratory. GS has the potential to provide patients with unbiased, rapid, and accurate molecular diagnostics that transcend diverse clinical indications and complex conditions. Therefore, the use in drug development for genetic and rare diseases across the region will act as one of the key factors driving the growth of the genotyping markets.

North America Genotyping Market Segmentation

The North America genotyping market is segmented by products and services, technology, application, end user, and country.
  • Based on products and services, the market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment is dominating the market in 2022.
  • Based on technology, the market is segmented into microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption/ionization-time of flight (Maldi-ToF) mass spectrometry, polymerase chain reaction (PCR), and others. The PCR segment is dominating the market in 2022.
  • Based on application, the market is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and others. The diagnostics and personalized medicine segment is dominating the market in 2022.
  • Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and others. The diagnostics and research laboratories segment is dominating the market in 2022.
  • Based on country, the market is segmented into the US, Canada, and Mexico. Further, the US is dominating the market in 2022.
A few key players dominating the North America genotyping market are BioTek Instruments, Inc.; Eurofins Genomics; F. Hoffmann-La Roche Ltd.; Illumina, Inc.; Integrated DNA Technologies, Inc.; MERCK KGaA; QIAGEN; Thermo Fisher Scientific Inc; and TrimGen Corporation.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Genotyping Market - By Product and Services
1.3.2 North America Genotyping Market - By Technology
1.3.3 North America Genotyping Market - By Application
1.3.4 North America Genotyping Market - By End User
1.3.5 North America Genotyping Market - By Country
2. North America Genotyping Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Genotyping Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Experts Opinion
5. North America Genotyping Market- Key Market Dynamics
5.1 Market Drivers
5.1.1 Use of Genotyping in Drug Development for Genetic and Rare Diseases
5.1.2 Technological Advancements and Rising R&D Investments in Pharmaceutical and Biotechnology
5.2 Market Restraints
5.2.1 High Cost of Equipment and Shortage of skilled Professionals required for Genotyping process
5.3 Market Opportunities
5.3.1 Wide Applications of Genotyping
5.4 Future Trends
5.4.1 Rising focus on Personalized Medicine
5.5 Impact analysis
6. Genotyping Market- North America Analysis
6.1 North America Genotyping Market Revenue Forecast and Analysis
7. North America Genotyping Market- by Product and Services
7.1 Overview
7.2 North America Genotyping Market, By Product and Services, 2022 & 2028 (%)
7.3 Reagents and Kits
7.3.1 Overview
7.3.2 Reagents and Kits: North America Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
7.4 Genotyping Services
7.4.1 Overview
7.4.2 Genotyping Services: North America Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
7.5 Bioinformatics
7.5.1 Overview
7.5.2 Bioinformatics: North America Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
7.6 Instruments
7.6.1 Overview
7.6.2 Instruments: North America Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
8. North America Genotyping Market- by Technology
8.1 Overview
8.2 North America Genotyping Market Share by Technology - 2022 & 2028 (%)
8.3 Polymerase Chain Reaction (PCR)
8.3.1 Overview
8.3.2 Polymerase Chain Reaction: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
8.4 Capillary Electrophoresis (CE)
8.4.1 Overview
8.4.2 Capillary Electrophoresis: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
8.5 Sequencing
8.5.1 Overview
8.5.2 Sequencing: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
8.6 Microarrays
8.6.1 Overview
8.6.2 Microarrays: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
8.7 Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry
8.7.1 Overview
8.7.2 Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
9. North America Genotyping Market-by Application
9.1 Overview
9.2 North America Genotyping Market Share by Application - 2022 & 2028 (%)
9.3 Diagnostics and Personalized Medicine
9.3.1 Overview
9.3.2 Diagnostics and Personalized Medicine: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
9.4 Pharmacogenomics
9.4.1 Overview
9.4.2 Pharmacogenomics: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
9.5 Animal Genetics
9.5.1 Overview
9.5.2 Animal Genetics: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
9.6 Agricultural Biotechnology
9.6.1 Overview
9.6.2 Agricultural Biotechnology: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
10. North America Genotyping Market- by End User
10.1 Overview
10.2 North America Genotyping Market Share by End User- 2022 & 2028 (%)
10.3 Diagnostic and Research Laboratories
10.3.1 Overview
10.3.2 Diagnostic and Research Laboratories: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
10.4 Pharmaceutical and Biopharmaceutical Companies
10.4.1 Overview
10.4.2 Pharmaceutical and Biopharmaceutical Companies: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
10.5 Academic Institutes
10.5.1 Overview
10.5.2 Academic Institutes: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
10.6 Others
10.6.1 Overview
10.6.2 Others: North America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
11. North America Genotyping Market- Country Analysis
11.1 North America: Genotyping Market Revenue and Forecasts to 2028
11.1.1 Overview
11.1.3 North America: Genotyping Market, by Country, 2022 & 2028 (%)
11.1.3.1 US: Genotyping Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.1.1 Overview
11.1.3.1.2 US: Genotyping Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.1.3 US: Genotyping Market, by Product and Services, 2019-2028 (US$ Million)
11.1.3.1.4 US: Genotyping Market, by Technology, 2019-2028 (US$ Million)
11.1.3.1.5 US: Genotyping Market, by Application, 2019-2028 (US$ Million)
11.1.3.1.6 US: Genotyping Market, by End User, 2019-2028 (US$ Million)
11.1.3.2 Canada: Genotyping Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.2.1 Overview
11.1.3.2.2 Canada: Genotyping Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.2.3 Canada: Genotyping Market, by Product and Services, 2019-2028 (US$ Million)
11.1.3.2.4 Canada: Genotyping Market, by Technology, 2019-2028 (US$ Million)
11.1.3.2.5 Canada: Genotyping Market, by Application, 2019-2028 (US$ Million)
11.1.3.2.6 Canada: Genotyping Market, by End User, 2019-2028 (US$ Million)
11.1.3.3 Mexico: Genotyping Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.3.1 Overview
11.1.3.3.2 Mexico: Genotyping Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.3.3 Mexico: Genotyping Market, by Product and Services, 2019-2028 (US$ Million)
11.1.3.3.4 Mexico: Genotyping Market, by Technology, 2019-2028 (US$ Million)
11.1.3.3.5 Mexico: Genotyping Market, by Application, 2019-2028 (US$ Million)
11.1.3.3.6 Mexico: Genotyping Market, by End User, 2019-2028 (US$ Million)
12. North America Genotyping Market Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 F. HOFFMANN-LA ROCHE LTD.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 INTEGRATED DNA TECHNOLOGIES, INC. (DANAHER)
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 QIAGEN
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 MERCK KGaA
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 EUROFINS GENOMICS
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.6 THERMO FISHER SCIENTIFIC INC.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 BioTek Instruments, Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 TRIMGEN CORPORATION
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Financial Overview
13.8.4 SWOT Analysis
13.8.5 Key Developments
13.9 Illumina, Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms

Companies Mentioned

  • BioTek Instruments, Inc.
  • Eurofins Genomics
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • MERCK KGaA
  • QIAGEN
  • Thermo Fisher Scientific Inc
  • TrimGen Corporation

Table Information